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ABSTRACT
Objective: The objective of the selective EBM review is to determine whether or not “Is Sadenosylmethionine (SAMe) an Effective Drug to Help Treat Patients with Depression?”
Study Design: A systematic review of three randomized controlled trials (RCTs) published
between 2016-2020.
Data Sources: All three RCTs were discovered using PubMed. The articles were published in
English in peer-reviewed journals and selected based on applicability to the clinical question.
Outcome Measured: A reduction in depressive symptoms was the outcome measured in all
three studies using the Montgomery-Asbery Depression Rating Scale (MADRS). The mean
change in baseline was calculated once intervention was received.
Results: In the RCT led by Sarris J, Murphy J, Stough C, et al., monotherapy with SAMe in
combination with co-factor vitamin B12 and folininc acid led to a reduction in depressive
symptoms compared with the control group (P = 0.13), indicated by a mean change from
baseline of -11.4. In the RCT led by Sarris J, Bryne GJ, Bousman C, et al., adjunctive therapy
with SAMe, in combination with co-factor B12 and folinic acid, led to a reduction in depressive
symptoms, indicated by a mean change from baseline of -11.4 (P = 0.51). Lastly, Sarris J, Byrne
GJ, Stough C, et al. illustrated a reduction in depressive symptoms using a nutraceutical
combination with SAMe, indicated by a mean change from baseline of -9.95 with a statistical
significance of P = 0.33 in the SAMe treatment group.
Conclusion: All three studies in this review demonstrated that SAMe did not lead to a
significant reduction in depressive symptoms as measured by the MADRS. In fact, two of the
three studies showed a greater reduction in depressive symptoms with the placebo than with
intervention with SAMe. This suggests that SAMe is not an effective or beneficial treatment for
patients with depression. Due to high placebo response rates, future studies should include a
placebo run-in period.
Key Words: S-adenosylmethionine, depression
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INTRODUCTION
Major depressive disorder (MDD) is a medical illness characterized by the presence of
five or more cardinal symptoms with at least one symptom being depressed mood or anhedonia.1
These symptoms must occur at least two weeks in duration and cannot be attributed to another
medical cause or effects of substance use.1 Depression is extremely common and affects more
than 300 million people worldwide.1 The prevalence of depression in US adults is 6.7%, with an
estimated lifetime risk as high as 30% for having at least one major depressive episode.1 In the
primary care setting, 30% of all patients have depressive symptoms.2 Depression is quite
disabling and can also lead to serious outcomes, such as suicide. Depression-related suicide is the
second leading cause of death in adults 18-25 years old.1 Depression costs the US an estimated
$210.5 billion per year and accounts for about 10.6% of physician office visits.3,4
The exact etiology of depression is unknown; however, studies suggest it is a result of a
complex interplay between several different factors. Evidence suggests that there is either a
decrease in the number of monoamines or malfunction of them that causes depression.5 These
monoamines include serotonin, norepinephrine, and dopamine.5 Most antidepressants enhance
the availability of serotonin, norepinephrine, or dopamine, illustrating that these three
monoamines play a central role in depression.5 Other evidence demonstrates neurotrophic and
endocrine factors play a role.5 Studies show that depression is associated with loss of
neurotrophic support.5 This theory is also supported with the evidence that some antidepressants
work by increasing neurogenesis and synaptic activity.5
There are several treatment options that can be used for depression, including both
pharmacologic and non-pharmacologic options, as well as a combination of the two.
Pharmacologic options include SSRIs, such as sertraline and fluoxetine, SNRIs, such as
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venlafaxine and duloxetine, Tricyclic antidepressants (TCAs), such as amitriptyline, monoamine
oxidase inhibitors (MAOIs), such as phenelzine, and atypical agents, such as bupropion and
mirtazapine. Cognitive therapy can be used as a non-pharmacologic option, as well as an
addition to medications. In the most severe and refractory cases, electroconvulsive therapy can
be used.
Cognitive therapy alone has shown some success when treating patients with depression
but is more commonly effective when used in addition to pharmacologic agents. The medications
mentioned above have proven to be effective in depression; however, patients do not always
respond to them or are not always able to tolerate them due to unwanted side effects. Common
side effects include weight gain, sexual dysfunction, and anxiety. Although more rare, other side
effects include risk of QT prolongation and increased risk of suicidal idealation in adults younger
than 25 years old. These limitations of undesirable side effects and some patients’ resistance to
standard therapy emphasizes the need for other treatment options. SAMe is a nutraceutical that
has been used to treat depression in European countries but is not currently approved as a drug in
the US. SAMe is associated with much milder side effects compared to those of the
antidepressants.6 Although the exact mechanism of SAMe is unknown, studies suggest it
enhances the activity of monomanias, similar to the mechanism of action as antidepressants, and
increases concentrations of norepinephrine and serotonin in the brain.6
This paper uses three randomized controlled trials (RCTs) to assess the efficacy of SAMe
as an alternative treatment option for depression.
OBJECTIVE
The objective of the selective EBM review is to determine whether or not “Is Sadenosylmethionine (SAMe) an Effective Drug to Help Treat Patients with Depression?”
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METHODS
The three articles discussed in this systematic review were found in published peerreviewed journals. The articles were found on PubMed using keywords “S-adenosylmethionine”
and “depression.” All articles were published in English and found using an exclusion criteria of
articles published before 2016 and secondary research. All three of the studies included are
double-blind, randomized, controlled trials published after 2016. The statistics used in these
articles to measure a decreased in depressive symptoms include a mean change from baseline,
using the Montgomery-Asbery Depression Rating Scale, and p-values.
All articles in this systematic review were chosen based on the applicability of the
clinical question being asked. These articles were selected because they all include a patientoriented outcome that helps answer whether or not SAMe is an effective drug to help treat
patients with depression. These articles were also chosen based on their populations, intervention
with SAMe, and outcome measured. The population of the studies in this selective EBM review
included patients ages 18-75 years old diagnosed with mild-severe major depressive disorder.
Table 1 illustrates the demographics of each of these studies, individually. Intervention with
SAMe, whether as monotherapy or as adjunctive therapy was another criterion. Lastly, the
outcomes measured were decrease in depressive symptoms all using the Montgomery-Asbery
Depression Rating Scale (MADRS).
OUTCOME MEASURED
All three studies used the Montgomery-Asbery Depression Rating Scale (MADRS), a
questionnaire that measures the severity of depression. MADRS assesses ten factors including
apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration
difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is
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graded on a 0-6 scale and summed to get a total score, ranging from 0-60. Higher scores are
associated with greater depressive severity. The outcome measured in this review is a decrease in
depressive symptoms using the MADRS.
Table 1. Demographics & Characteristics of Included Studies
Study

Type

#
Pts

Age
(yrs)

Inclusion
Criteria

Exclusion
Criteria
Patients currently
taking an
antidepressant or any
other mood
modulating drug or
nutraceutical. Patients
with severe
depression, suicide
idealation, or those
who failed three or
more trials of therapy.
Patients with other
medical or mental
disorders.
Patients currently
taking MAOIs,
TCAS, or specified
nutraceuticals.
Patients with suicide
idealation or those
who have failed three
or more trials of
therapy. Patients with
other medical or
mental disorders.

8

SAMe vs.
Placebo

30

Combination of
SAMe, co-factor
B12, and folinic
acid vs. Placebo
as adjunctive
therapies

Patients currently
taking MAOIs,
TCAs, or specified
nutraceuticals.
Patients presenting
with suicide
idealation or those
who have failed three
or more trials of
therapy. Patients with
other medical or
mental disorders.

45

Combination of
SAMe, folinic
acid, omega-3
fatty acid, 5HTP, and zinc
picolinate vs.
Placebo as
adjunctive
therapies

Sarris7
(2020)

RCT

49

18-75
years
of age

Patients 18-75 who
met the DSM-5
criteria for MDD,
presenting with
mild-moderate
depression, and
who were currently
not taking
antidepressants.

Sarris8
(2018)

RCT

107

18-75
years
of age

Patients 18-75 who
met the DSM-5
criteria for MDD,
presenting with
moderate-severe
depression, and
currently taking an
SSRI, SNRI, NaRI,
5-cHT2c
antagonist, or
tetracyclic
antidepressant.

Sarris9
(2019)

RCT

158

18-70
years
of age

Patients 18-70 years
old who met the
DSM-5 criteria for
MDD, presenting
with moderatesevere depression,
and were currently
on an
antidepressant or
some other stable
treatment as usual
medical care.

W/
D

Interventions
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RESULTS
All the studies in this review looked at patients who met the DSM-5 criteria for Major
Depressive Disorder (MDD). Sarris J, Murphy J, Stough C, et al. conducted a double-blind,
randomized controlled trial to assess the efficacy of SAMe as monotherapy for depression. There
were 49 patients, ages 18-75, enrolled in this study. The patients in this specific study had mildmoderate depression and were not taking any antidepressants. Patients were randomized in a 1:1
ratio and assigned to either the experimental group or control group. The experimental group
received 800 mg/day of SAMe, in combination with co-factor vitamin B12 and folinic; whereas
the control group received a placebo.7 Each group received monotherapy whether with the SAMe
combination or the placebo. Patients received treatment for a total of 8 weeks in duration. Five
participants in total, one in the SAMe group and four in the placebo group, experienced
worsening of depression and were dismissed from the study.7 Additionally, two more
participants left the study in the SAMe group, but the reason as to why was not provided.7 Lastly,
another patient left the placebo group for adverse effects.7 These individuals were not included in
the final analysis.
The primary outcome evaluated in this study was decrease in the number of depressive
symptoms. Mean values were used to measure the outcomes after receiving treatment. The
SAMe group showed a decrease in mean values of -9.90 ± 1.49, resulting in a mean change from
baseline of -11.4.7 The placebo group showed a decrease in mean values of -12.5 ± 1.54,
resulting in a mean change from baseline of -7.70.7 Although the mean change in baseline was
greater in the SAMe group than the placebo group, there was not a statistically significant
difference between groups or after the intervention (P = 0.13). These results are summarized in
Table 2 below.
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Table 2. MADRS Change in Depressive Symptoms from Baseline to Study Endpoint7

SAMe Group
Placebo
Group

Before
Treatment
(Mean ± SD)
22.4 ± 2.01
22.2 ± 3.11

Week 8
(Mean ±
SD)
9.90 ± 1.49
12.5 ± 1.54

Mean Change from
Baseline

Pvalue

-11.4
-7.70

0.13

Sarris J, Bryne GJ, Bousman C, et al. led another similar double-blind, randomized
controlled trial that assessed the efficacy of a combination of SAMe as an adjunctive treatment
for depression. In this study, 800 mg of SAMe was combined with folinic acid and co-factor
vitamin B12.8 This study looked at 107 patients, ages 18-75, with moderate to severe depression,
who were already taking an SSRI, SNRI, NaRI, 5-cHT2c antagonist, or tricyclic antidepressant.
This study also ran for a duration of 8 weeks and patients were assigned to either receive the
combination with SAMe or a placebo as an adjunctive therapy. There were 55 participants
assigned to the SAMe group and 52 assigned to the placebo group. Of the 107 participants, only
77 of them completed the entire 8 weeks, with 40 trial completers in the SAMe group and 37
completers in the placebo group.8 Seven patients experienced adverse events, 5 in the SAMe
group and 2 in the placebo group.8 Two more patients in the SAMe group discontinued the study
for worsening of symptoms.8 Additionally, 21 other participants were dismissed from the study
either due to their own decision, loss of follow up, non-compliance, or unrelated medical events.8
These participants were not included in the final analysis.
A decrease in the number of depressive symptoms was also the main outcome measured
in this study. Mean values were used to measure the outcomes after receiving the treatment for 8
weeks. The SAMe group illustrated a mean change from baseline of -11.4.8 The placebo group
showed a mean change from baseline of -12.1.8 In this study, the placebo group had a slightly

Flanigan, SAMe 7
greater mean change from baseline than that of the SAMe group; however, difference in the
values between groups and following the intervention did not reach the level of statistical
significance (P = 0.511). These results are summarized in Table 3 below.
Table 3. Change in Primary Endpoints in Sarris J, Bryne GJ, Bousman C, et al. Study8
SAMe Group
Placebo Group

Mean Change from Baseline
11.4 ± 7.54
-12.1 ± 7.02

P-value
0.511

Lastly, Sarris J, Byrne GJ, Stough C, et al. conducted another double-blind, randomized
controlled trial that assessed a combination of SAMe with other nutraceuticals as an effective
treatment for MDD. This studied had 158 patients, ages 18-70, who had moderate to severe
depression. This study also lasted 8 weeks in duration and included patients who were currently
on an antidepressant or other stable treatment regimen. Patients either received a combination of
SAMe, folinic acid, omega-3 fatty acid, 5-HTP, and zinc picolinate as an adjunctive therapy or a
placebo.9 Of the 158 patients that were initially enrolled in the study, only 113 fully completed
the entire trial with 56 completers in the SAMe group and 57 completers in the placebo group.
Twelve of the participants discontinued the study due to adverse events, 9 from the SAMe group
and 3 from the placebo group.9 Thirty-three other participants discontinued intervention due to
the investigators or their own decision, noncompliance, unrelated medical issue, or loss to follow
up.9 These participants were not included in the final analysis.
The primary outcome evaluated in this study was a decrease in the number of depressive
symptoms. Mean values were used to measure the outcomes after receiving treatment. The
SAMe group had a mean change of baseline of -9.5 ± 8.57. The placebo group showed a mean
change from baseline of -11.7 ± 7.82. 9 Although the mean change in baseline was greater in the
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SAMe group than the placebo group, analysis of group-by-time ANOVA did not show a
statistically significant difference (P = 0.33). These results are summarized in Table 4 below.
Table 4. Change in Primary Endpoints in Sarris J, Byrne GJ, Stough C, et al. Study 9
SAMe Group
Placebo Group

Mean Change from Baseline
-9.5 ± 8.57
-11.7 ± 7.82

P-value
0.33

DISCUSSION
Major depressive disorder is a very common and disabling health condition. Although
there are both non-pharmacologic and pharmacologic options that have shown some success in
treating depression, they are not always effective. Some patients do not always respond to
treatment and others are unable to tolerate medication due to undesirable side effects. SAMe, a
nutraceutical used to treat depression in Europe, has been associated with few side effects.
However, other barriers with the use of SAMe exist including its long-term safety and possible
interactions with other drugs and dietary supplements that increase levels of serotonin.10 In the
United States, SAMe is only sold as a dietary supplement. It does not have the FDA’s approval
for any medical use; however, its use as been evaluated in several studies for osteoarthritis and
liver diseases, in addition to depression.10 Although there are not contraindications with use of
SAMe, evidence suggests it is not safe in those with bipolar disorder or those who are
immunocompromised.10 Additionally, there is not enough evidence to understand its safety in
pregnancy.10
This review evaluated the effectiveness of SAMe as treatment for depression. None of the
three studies found any statistically significant decrease in depressive symptoms with use of
SAMe as monotherapy or as adjunctive therapy. In fact, of all three studies, only the study by
Sarris J, Murphy J, Stough C, et al. showed a greater reduction in depressive symptoms with
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SAMe compared to that of the placebo. Although an absolute difference was observed between
the two groups, the p-values of both the intervention and placebo groups illustrate no statistical
significance. In both studies by Sarris J, Bryne GJ, Bousman C, et al. and Sarris J, Byrne GJ,
Stough C, et al. the placebos achieved a greater reduction in depressive symptoms than the actual
interventions with SAMe. Furthermore, the groups in these studies had p-values that revealed no
statistical significance in these findings. In summary, these studies showed no support for SAMe
as an effective treatment for depression.
The studies in this selective EBM review all had their fair share of bias and limitations.
None of the studies carried out a worst-case analysis which compromised the validity of the
results. The three studies also all used small sample sizes and only had a short duration of
treatment, which further compromised the validity and reliability of the results. Furthermore, the
studies all were found to have high placebo response rates which could have obscured the results.
Other limitations are directly related to the approach of each study and how they were all
designed slightly different. In the study by Sarris J, Murphy J, Stough C, et al., SAMe was used
alone as monotherapy, whereas, in the studies by Sarris J, Bryne GJ, Bousman C, et al. and
Sarris J, Byrne GJ, Stough C, et al., SAMe was used as adjunctive therapy. Furthermore, in the
studies by Sarris J, Murphy J, Stough C, et al. and Sarris J, Bryne GJ, Bousman C, et al., SAMe
was combined with folinic acid and co-factor vitamin B12, while in the study by Sarris J, Byrne
GJ, Stough C, et al., SAMe was combined with folinic acid, omega-3 fatty acid, 5-HTP, and zinc
picolinate. In the study by Sarris J, Murphy J, Stough C, et al., only patients with mild-moderate
depression were enrolled, while in the studies by Sarris J, Bryne GJ, Bousman C, et al. and Sarris
J, Byrne GJ, Stough C, et al., patients with moderate-severe depression were enrolled. These
distinct qualities made direct comparison very difficult amongst the three studies.
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CONCLUSION
In conclusion, SAMe did not prove to be effective in treating patients with depression.
There was no statistically significant reduction in depressive symptoms between the placebo or
intervention groups in any of the studies. In fact, in two of the three studies SAMe failed to
outperform the placebo, altogether. Future studies should incorporate larger sample sizes to help
minimize expectancy bias, as well as allow a longer duration for intervention and consider using
a higher dosage of SAMe. Additionally, future studies should try to achieve a more stable
placebo-response pattern due to the high placebo response rates. Future studies could also try
different nutraceutical combinations then the ones used in these studies. Currently, there are no
studies being conducted on SAMe and its role in depression in the United States; however,
hopefully future studies can be carried out to help find other treatment options for patients
struggling with depression.
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